CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Azacitidine Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2020-12-18. Latest FDA row update: 2026-10-03.
FDA lists 9 package records, with companies: Accord Healthcare Inc., Armas Pharmaceuticals Inc, Armas Pharmaceuticals Inc., BluePoint Laboratories, Bristol Myers Squibb Co., Celgene Corporation, Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Inc., Eugia US LLC, Fresenius Kabi USA, LLC, Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals USA, Inc., Meitheal Pharmaceuticals Inc., Meitheal Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc.. Package NDCs: 0143-9606-01, 16729-306-10, 43598-305-62, 55150-393-01, 59572-102-01, 63323-771-39, 68001-313-56, 71288-115-30, 72485-201-01.
FDA shortage reason: Demand increase for the drug; Discontinuation of the manufacture of the drug; Other
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Accord Healthcare Inc. | 16729-306-10 | Azacitidine, Injection, 100 mg (NDC 16729-306-10) | Available | 2026-10-03 |
| Armas Pharmaceuticals Inc | 72485-201-01 | Azacitidine, Injection, 100 mg (NDC 72485-201-01) | Limited Availability | 2026-06-08 |
| Bristol Myers Squibb Co. | 59572-102-01 | Vidaza, Injection, 100 mg (NDC 59572-102-01) | Available | 2026-10-02 |
| Dr. Reddy's Laboratories, Inc. | 43598-305-62 | Azacitidine, Injection, 100 mg (NDC 43598-305-62) | Available | 2026-09-29 |
| Eugia US LLC | 55150-393-01 | Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01) | Unavailable | 2026-10-02 |
| Fresenius Kabi USA, LLC | 63323-771-39 | Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39) | Unavailable | 2026-09-15 |
| Hikma Pharmaceuticals USA, Inc. | 0143-9606-01 | Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01) | Available | 2026-09-18 |
| Meitheal Pharmaceuticals, Inc. | 71288-115-30 | Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30) | Available | 2026-08-27 |
| Teva Pharmaceuticals USA, Inc. | 68001-313-56 | Azacitidine, Injection, 100 mg (NDC 68001-313-56) | Unavailable | 2026-10-01 |
Source facts
Grouped generic ingredient: Azacitidine Injection · 9 package records
Therapeutic categories: Oncology
Dosage forms: Injection
Routes: INTRAVENOUS, SUBCUTANEOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.